Skip to main content

$0.125 (0.00%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
19 May 2025 at 7:48am
Register to track EMD and receive email alerts.

Dosing Commences For EMD-RX5 Phase 1 Human Clinical Trial

StockBot

416,823 posts

EMD released this announcement to the ASX on 7 April 2022, 9:45. The announcement is not marked as price sensitive, and is 5 page(s) in length and 453.01kb in size.

You can view all announcements from EMD and see how they appear on a price chart on the announcements page.

At the date of this announcement, EMD was 0.086% short sold according to ASIC data. It was ranked the 470th most shorted stock on the ASX. It remains ranked 600th as of the latest reported data (17 April 2025).

Other Recent Announcements from EMD
Trading Halt 29 June 2023, 9:33
Emyria Receives Ethics Approval for MDMA-assisted Therapy 8 June 2023, 9:10
Section 708A(5)(e) Notice 10 May 2023, 18:37
Dosing Commences For EMD-RX5 Phase 1 Human Clinical Trial 7 April 2022, 9:45
Broker Briefing Presentation 24 March 2022, 15:09
Emyria to present webinar, March 24th 23 March 2022, 9:32
Letter to Shareholders - Adjourned General Meeting 18 March 2022, 18:19
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track EMD and receive email alerts.